Study of Colchicine to Treat Heart Disease in Adults with Chronic Kidney Disease Ages 21 to 80

What this Trial Is About

Researchers are evaluating the effectiveness and safety of colchicine in patients with chronic kidney disease, specifically those with uremic cardiomyopathy. This Phase 2 study aims to understand how colchicine, an anti-inflammatory drug, affects heart function in this population. The study compares colchicine to a placebo to assess its impact on heart strain and inflammation. Participants are randomly assigned to receive either colchicine 0.3 mg once daily or a placebo once daily. The study is blinded so that neither the participants nor the researchers know who receives which treatment. The treatment lasts for 4 weeks, during which changes in heart function and inflammation levels are monitored. Throughout the study, participants undergo evaluations including heart imaging to measure left ventricular strain, systolic and diastolic function, volumes, and size, along with tests for systemic inflammation. The primary outcome is the change in left ventricular global longitudinal strain after 4 weeks. Safety and other heart-related measurements are also tracked to understand the effects of colchicine in this group. Participants are involved in regular study visits and assessments during the treatment period.

Anti-Inflammatory Treatment of Uremic Cardiomyopathy With Colchicine